This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-29. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
In 1985, Kidder expressed ambivalence toward continuing her career, and was quoted as saying: "I don't feel comfortable as a performer and I'm a big turkey as a movie star." She stated that the quote was reported out of context, but conceded: "I am in a weird frame of mind at the moment. I know acting is not going to be enough for me for the rest of my life. This business is very hard on women at a certain age, and I never want to end up just having to accept what's offered me. So, I am anxious to direct, to have options." In 1986, she was selected as the English narrator for the Japanese animated series The Wonderful Wizard of Oz. In 1987, Kidder reprised her Lois Lane role in Superman IV: The Quest for Peace (1987), which she filmed in 1986. Body of Evidence (1988), a CBS Movie of the Week, cast Kidder as a nurse who suspects that her medical pathologist husband is a serial killer.
== Impact and aftermath == Syrian rebels took advantage of the war, the heavy losses suffered by Hezbollah, and Hezbollah's absence in Syria to launch the 2024 Syrian opposition offensive on 27 November 2024 to overrun Syria's government-held territories. Hezbollah, which had previously sent forces, said they would not deploy troops, but later sent "supervising forces" to unsuccessfully attempt to repel the 2024 Homs offensive, as Homs is a key transport route for Iran to supply Hezbollah. In December 2024, the fall of Assad's Baathist regime in Syria was another blow to its Lebanese ally, Hezbollah, which was already weakened because of Israeli military actions. Following major operations in 2024, numerous analysts and experts have characterized the outcome as a significant victory for Israel. The Institute for the Study of War reported that Israeli operations effectively degraded Hezbollah's capabilities, leading to a ceasefire agreement on November 26, 2024, which mandated Hezbollah's disarmament in southern Lebanon. Hezbollah failed to accomplish its goal of compelling Israel to cease operations in the Gaza Strip, resulting in a weakened position within the region. Similarly, experts from the Atlantic Council noted that Israel's military actions, including the elimination of Hezbollah's leader, Hassan Nasrallah, significantly diminished the group's operational effectiveness.
The Department works at the intersection of organic chemistry (chemistry of natural products, chemistry of macrocyclic compounds, chemistry of elementorganic compounds), supramolecular chemistry (solution and self-process chemistry) and molecular biology. The head of the Department is Professor Igor S. Antipin, a corresponding member of the Russian Academy of Science, Doctor of Chemistry. The Department conducts research in the following fields:
The ligated mRNA-DNA-puromycin library is translated in Red Nova Lysate (Novagen) or E. coli S30 Extract System (Promega), resulting in peptides covalently linked in cis to the encoding mRNA. The in vitro translation can also be done in a PURE (protein synthesis using recombinant elements) system. PURE system is an E. coli cell-free translation system in which only essential translation components are present. Some components, such as amino acids and aminoacyl-tRNA synthases (AARSs) can be omitted from the system. Instead, chemically acylated tRNA can be added into the PURE system. It has been shown that some unnatural amino acids, such as N-methyl-amino acid accylated tRNA can be incorporated into peptides or mRNA-peptide fusions in a PURE system. After translation, the single-stranded mRNA portions of the fusions will be converted to heteroduplex of RNA/DNA by reverse transcriptase to eliminate any unwanted RNA secondary structures, and render the nucleic acid portion of the fusion more stable. This step is a standard reverse transcription reaction. For instance, it can be done by using Superscript II (GIBCO-BRL) following the manufacturer's protocol.
Sources: en.wikipedia.org
Fermium was first discovered in the fallout from the 'Ivy Mike' nuclear test (1 November 1952), the first successful test of a hydrogen bomb. Initial examination of the debris from the explosion had shown the production of a new isotope of plutonium, 244Pu: this could only have formed by the absorption of six neutrons by a uranium-238 nucleus followed by two β− decays. At the time, the absorption of neutrons by a heavy nucleus was thought to be a rare process, but the identification of 244Pu raised the possibility that still more neutrons could have been absorbed by the uranium nuclei, leading to new elements. Element 99 (einsteinium) was quickly discovered on filter papers which had been flown through clouds from the explosion (the same sampling technique that had been used to discover 244Pu). It was then identified in December 1952 by Albert Ghiorso and co-workers at the University of California at Berkeley. They discovered the isotope 253Es (half-life 20.5 d) that was made by the capture of 15 neutrons by uranium-238 nuclei – which then underwent seven successive beta decays:
== Knudsen cell == The Knudsen cell is used to measure the vapor pressures of a solid with very low vapor pressure. Such a solid forms a vapor at low pressure by sublimation. The vapor slowly effuses through a pinhole, and the loss of mass is proportional to the vapor pressure and can be used to determine this pressure. The heat of sublimation can also be determined by measuring the vapor pressure as a function of temperature, using the Clausius–Clapeyron relation.
Starting in 2007, Jimmy John's began sponsoring NASCAR, first with Steven Wallace in 2007 and 2008. In 2009 and 2010, Jimmy John's sponsored Kevin Harvick in the NASCAR Nationwide Series. In 2011, Jimmy John's and Richard Childress Racing reached a multi-year agreement to sponsor Harvick for the Sprint Cup Series. The 2014 sponsorship continued with Harvick and the Stewart–Haas Racing team. On September 13, 2014, Jimmy John's became the title sponsor of the Jimmy John's Freaky Fast 300 at Chicagoland Speedway. Harvick won the 2014 NASCAR Sprint Cup Championship, giving Jimmy John's their first championship. From 2010 to 2019, Jimmy John's entered into an Ultimate Fighting Championship sponsorship with Brock Lesnar with logos appearing on his trunks. This sponsorship extended to WWE upon Lesnar's return to that company in 2012, making him the only WWE performer in history to be permitted such a deal. In 2015, Jimmy John's co-sponsored the RCH Factory Racing Supercross and Motocross team featuring Ken Roczen. The team contested both the Monster Energy AMA Supercross and the Lucas Oil Pro Motocross championships. In June, Jimmy John's sponsored former NASCAR champion Rusty Wallace for his Speed Energy Formula Off-Road debut at the 2015 X Games.
Sources: en.wikipedia.org
=== Main === Kerry Washington as Olivia Pope Scott Foley as Jacob "Jake" Ballard Darby Stanchfield as Abigail "Abby" Whelan Katie Lowes as Quinn Perkins Guillermo Diaz as Diego "Huck" Muñoz Jeff Perry as Cyrus Beene Joshua Malina as Attorney General David Rosen Bellamy Young as Senator Melody "Mellie" Grant Portia de Rossi as VP's Chief of Staff Elizabeth North Joe Morton as Rowan "Eli" Pope Cornelius Smith Jr. as Marcus Walker Tony Goldwyn as President Fitzgerald "Fitz" Thomas Grant III
== External links == "Discrimination des femmes à l'embauche" [Discrimination against women in hiring] (in French). Archived from the original on March 28, 2007. "Hommes et femmes" [Men and women]. Observatoire des Inégalités (in French). Archived from the original on February 19, 2007. "Lutte contre les discriminations et promotion de l'égalité" [Fighting discrimination and promoting equality]. Defenseurs des droits (in French). Archived from the original on June 13, 2017. "La discrimination des femmes : un sujet d'actualité" [Discrimination against women: a topical issue]. CentrOjeunes (in French). December 6, 2012. Archived from the original on August 8, 2016. "Discrimination des femmes à l'embauche" [Discrimination against women in hiring] (in French). Archived from the original on March 28, 2007. "Haut conseil à l'égalité des droits" [High Council for Equal Rights]. Haut Conseil a L'égalité entre les femmes et les hommes (in French). Archived from the original on May 22, 2013. "Secrétariat d'état chargé de l'égalité entre femmes et hommes et de la lutte contre les discriminations" [State Secretariat for Gender Equality and Anti-Discrimination]. Haut Conseil a L'égalité entre les femmes et les hommes (in French). Archived from the original on January 7, 2013. "Maison de la justice et du droit" [House of Justice and Law] (in French). Archived from the original on April 12, 2013. "Association européenne contre les Violences faites aux Femmes au Travail" [European Association Against Violence Against Women at Work] (in French).
The open spaces of areolar connective tissue, a type of loose connective tissue Areolae (diatom), pores in the silica shell of diatoms Areole, a raised structure bearing spines on cacti Areola (lichen), a round to polygonal part of a surface of a crustose lichen Areola (entomology), a small ring of color or gap in wing margin of insects- see the Glossary of entomology terms. Areola, the open space created by higher venation of a leaf - see the Glossary of botanical terms
The muscular system is an organ system consisting of skeletal, smooth, and cardiac muscle. It permits movement of the body, maintains posture, and circulates blood throughout the body. The muscular systems in vertebrates are controlled through the nervous system although some muscles (such as the cardiac muscle) can be completely autonomous. Together with the skeletal system in the human, it forms the musculoskeletal system, which is responsible for the movement of the body.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.